Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Multiple Sclerosis Journal Année : 2021

Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis

Résumé

Background: Planning pregnancy in patients with active multiple sclerosis (MS) is highly challenging because treatment withdrawn may be associated with dramatic disease reactivation. Objective: To compare two strategies for women with active MS who were planning pregnancy: stopping natalizumab (1) at the end of the first trimester and (2) at conception. Methods: Standardized strategy for women with active MS was initiated in our department. Maintenance of natalizumab until the end of first trimester was recommended (“secured first trimester” (SFT)). When patients refused, they were advised to continue until conception (“secured conception” (SC)). Predictors of disease activity during pregnancy were assessed. Results: Forty-six pregnancies were prospectively followed (30 with SFT and 16 with SC). One congenital anomaly occurred in the SC group. The proportions of patients with relapse and disability progression during pregnancy were lower in the SFT than in the SC group (3.6% vs 38.5%, p < 0.005 and 3.6% vs 30.8%, p < 0.05, respectively). Predictors of relapse and disability progression during pregnancy were the time when natalizumab was stopped (conception vs end of first trimester) and the number of relapses during the year before natalizumab. Conclusion: Maintaining natalizumab during the first trimester may reduce the risk of disease reactivation during pregnancy in patients with active MS.

Domaines

Immunothérapie
Fichier non déposé

Dates et versions

hal-03537416 , version 1 (20-01-2022)

Identifiants

Citer

Sarah Demortiere, Audrey Rico, Adil Maarouf, Clémence Boutiere, Jean Pelletier, et al.. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Multiple Sclerosis Journal, 2021, 27 (5), pp.712-718. ⟨10.1177/1352458520912637⟩. ⟨hal-03537416⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More